Efficacy and safety of the dual SYK/JAK inhibitor cerdulatinib in patients with relapsed or refractory B-cell malignancies: Results of a phase I study.
Paul A HamlinIan W FlinnNina Wagner-JohnstonJan A BurgerGreg P CoffeyPamela B ConleyGlenn MichelsonJanet M LeedsKenneth DerYvonne KimAlice Sabalvaro-TorresMatt BirrellAnjali PandeyJohn T CurnutteManish R PatelPublished in: American journal of hematology (2019)